Results · Apr-Jun 2026
Solara Active Pharma Sciences Q1 FY27 results
Sales grew 20% to ₹382 crore from ₹319 crore in Apr-Jun 2025.
Operating profit grew 9% to ₹62 crore, an operating margin of 16.2% (down 1.6 points from a year ago).
Net profit grew 55% to ₹16.3 crore from ₹10.5 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −1%, net profit +70%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 381.6 | 319.2 | +20% |
| Operating profit (EBITDA) | 62.0 | 57.0 | +9% |
| Operating margin | 16.2% | 17.9% | −1.6 pts |
| Net profit | 16.3 | 10.5 | +55% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.